These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28430376)

  • 21. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
    Korman AM; Tyler KH; Kaffenberger BH
    Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
    [No Abstract]   [Full Text] [Related]  

  • 22. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Adler NR; Murray WK; Brady B; McCormack C; Pan Y
    Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
    [No Abstract]   [Full Text] [Related]  

  • 23. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
    Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
    Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
    [No Abstract]   [Full Text] [Related]  

  • 24. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

  • 26. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
    Wernham AGH; Shah F; Velangi S
    Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
    N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
    [No Abstract]   [Full Text] [Related]  

  • 29. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 30. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
    Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
    J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 33. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
    Mangana J; Buset CS; Dummer R
    JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
    [No Abstract]   [Full Text] [Related]  

  • 34. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 35. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
    Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
    JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
    [No Abstract]   [Full Text] [Related]  

  • 36. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
    Latchman J; Guastella A; Tofthagen C
    Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
    Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
    Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
    [No Abstract]   [Full Text] [Related]  

  • 38. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
    Meti N; Petrogiannis-Haliotis T; Esfahani K
    J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
    [No Abstract]   [Full Text] [Related]  

  • 39. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
    [No Abstract]   [Full Text] [Related]  

  • 40. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.